Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed to Treat Rare Diseases
Supporting Its Continued Commitment During Rare Disease Month to Making a Difference in the Lives of Patients Faced with Limited Treatment Options

Veristat’s growth has been propelled by our ability to offer our customers specialized solutions that accelerate their success